Table 1.
Clinical and laboratory characteristics
| Clinical and laboratory characteristics | Patients n = 20 | Controls n = 18 | p value |
|---|---|---|---|
| Age, (years) | 48 (46–52) | 50 (46–51) | 0.59 |
| Sex, male (%) | 15 (75%) | 13 (72%) | 0.57 |
| Race, white (%) | 20 (100%) | 18 (100%) | – |
| MI type, STEMI (%) | 13 (65%) | – | – |
| Time between MI and V1 (months) | 25 (19–38) | – | – |
| Time between CT and V1 (months) | – | 28 (7–42) | – |
| BMI (kg/m2) | 27 (24–29) | 27 (24–30) | 0.92 |
| Systolic blood pressure (mmHg) | 121 (118–136) | 122 (120–128) | 0.70 |
| Diastolic blood pressure (mmHg) | 80 (78–83) | 81 (77–89) | 0.46 |
| Family history of cardiovascular disease (%) | 8 (42%) | 3 (17%) | 0.09 |
| Smoking, active (%) | 3 (15%) | 2 (11%) | 0.67 |
| Smoking, past (%) | 9 (45%) | 6 (33%) | |
| Smoking, never (%) | 8 (40%) | 10 (56%) | |
| Acetylsalicylic acid use (%) | 20 (100%) | 1 (6%) | <0.0001 |
| Statin use (%) | 19 (95%) | 0 (0%) | <0.0001 |
| ACE inhibitor/ARB use (%) | 15 (75%) | 1 (6%) | <0.0001 |
| β-Blocker use (%) | 13 (65%) | 0 (0%) | <0.0001 |
| Ezetimibe use (%) | 4 (20%) | 0 (0%) | 0.07 |
| Total c (mmol/L) | 5.2 (4.5–5.7) | 5.5 (4.8–5.9) | 0.37 |
| LDLc (mmol/L) | 3.4 (2.9–3.6) | 3.4 (2.8–4.0) | 0.57 |
| HDLc (mmol/L) | 1.2 (1.0–1.4) | 1.4 (1.2–1.6) | 0.03 |
| Triglycerides (mmol/L) | 1.4 (1.0–2.0) | 1.2 (0.9–1.7) | 0.38 |
| Lipoprotein(a) (mg/dL) | 12.0 (5.9–38.4) | 14.1 (3.8–33.0) | 0.65 |
| Fasting glucose (mmol/L) | 5.2 (4.8–5.6) | 5.2 (4.9–5.3) | 0.56 |
| Creatinine (μmol/L) | 81 (72–97) | 82.5 (73–94) | 0.96 |
| Leukocyte count (10³/μL) | 5.5 (4.9–6.9) | 5.5 (4.9–6.4) | 0.87 |
| Neutrophil count (10³/μL) | 3.2 (2.5–4.3) | 3.0 (2.7–3.7) | 0.85 |
| Lymphocyte count (10³/μL) | 1.62 (1.3–1.9) | 1.7 (1.4–1.9) | 0.65 |
| Monocyte count (10³/μL) | 0.5 (0.5–0.6) | 0.5 (0.4–0.6) | 0.67 |
| Neutrophil percentage (% of leukocytes) | 54.7 (52.3–62.4) | 54.0 (51.7–59.9) | 0.74 |
| Lymphocyte percentage (% of leukocytes) | 30.3 (23.4–35.5) | 33.0 (25.9–35.8) | 0.55 |
| Monocyte percentage (% of leukocytes) | 8.8 (7.6–9.8) | 8.7 (7.7–10.3) | 0.95 |
| Neutrophil/lymphocyte ratio | 1.8 (1.5–2.4) | 1.6 (1.5–2.3) | 0.71 |
| Monocyte/lymphocyte ratio | 0.3 (0.2–0.4) | 0.3 (0.3–0.3) | 0.66 |
Data are presented as median and interquartile range for continuous- and percentages for categorical variables. See also Tables S1 and S2.
(ACE) angiotensin converting enzyme, (ARB) angiotensin receptor blocker, (BMI) body mass index, (CT) computed tomography scan, (HDLc) high-density lipoprotein cholesterol, (LDLc) low-density lipoprotein cholesterol, (MI) myocardial infarction, (STEMI) ST-elevation myocardial infarction, (Total c) total cholesterol.